21.02.2017 • NewsAstraZenecabreast cancerCanada

AstraZeneca Sells North American Zoladex Rights

(c) AstraZeneca
(c) AstraZeneca

AstraZeneca has agreed to sell the commercial rights for its cancer treatment Zoladex in the US and Canada for $250 million upfront to private equity-backed TerSera Therapeutics –  a US company specialized in acquiring and developing pharmaceutical products dedicated to select therapeutic areas. It will, however, continue to commercialize the drug in all markets outside of the US and Canada.

The Anglo-Swedish drugmaker has recently focused its recent R&D efforts on new areas such as immuno-oncology in an effort to offset expiring patents on some of its older drugs.

As part of the deal, AstraZeneca will also receive sales-related income through milestones worth up to $70 million, as well as recurring quarterly sales-based payments at what it said is a “mid-teen percent” of product sales. It will continue manufacturing the drug for TerSera.

First approved in the US and Canada in 1989, the injectable luteinizing hormone-releasing hormone agonist Zoladex is used to treat prostate cancer, breast cancer and certain benign gynecological disorders. In 2016, its sales totaled some $69 million in the US and Canada, and $816 million worldwide.

Mark Mallon, AstraZeneca’s executive vice president, global product & portfolio strategy, said the agreement will allow the company to retain a significant share of the value of Zoladex in the US and Canada, while concentrating its resources on innovative “new  oncology” medicines. He said it will also ensure that patients have continued access to the treatment.

The transaction, which does not include the transfer of any AstraZeneca employees or facilities and – the company stressed – does not impact its financial guidance for 2017, is expected to be wrapped up during this year’s first quarter, subject to customary closing conditions.  

AstraZeneca’s shares made gains last week when it reported positive results from clinical trials with Lynparza, a treatment for BRCA-mutated metastatic breast cancer. Some analysts view the drug as a potential blockbuster. The company’ largest shareholder, Woodford Investment Management, reportedly increased its holdings in the pharmaceutical manufacturer on the news.

Lynparza, AstraZeneca said, met its primary endpoint in the phase 3 trials, as initial findings from a study indicated that the drug’s safety profile was consistent with previous studies. Patients treated with Lynparza are said to have shown a “statistically significant and clinically meaningful improvement” in progression-free survival for metastatic breast cancer sufferers compared to those treated with chemotherapy.

Sean Bohen, AstraZeneca’s executive vice-president for global medicines development and chief medical officer, said the results were the first positive Phase 3 data for a PARP inhibitor beyond ovarian cancer. “This,” he said, “is highly encouraging for the development of our broad portfolio which aims to treat multiple cancers by targeting DNA damage response pathways."

In December 2016, the drugmaker’s application for sale of its new bladder cancer treatment durvalumab was been accepted by the US Food and Drug Administration. AstraZeneca previously said it saw durvalumab as a potential breakthrough treatment for several forms of cancer.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.